Statin use and the risk of esophageal cancer: a population-based case-control study

Bibliography

• Wong WW, Dimitroulakos J, Minden MD, HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apotosis. Leukemia 2002;16:508-19
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Hebert PR, Gaziano JM, Chan KS, Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21
   PubMed Web of Science ®Google Scholar
• Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Mascitelli L, Pezzetta F. Do statin prevent or promote cancer? Curr Oncol 2008;15:76-7
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Sandoval L, Band V, Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-9
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Marhin WH, Tokunaga J, Microarray and biochemical analysis of lovastatin-induced apotosis of squamous cell carcinoma. Neoplasia 2002;4:337-46
   PubMed Web of Science ®Google Scholar
• Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103:825-37
   PubMed Web of Science ®Google Scholar
• Hawk ET, Viner JL. Statins in esophageal cancer cell lines: promising lead? Am J Gastroenterol 2008;103:838-41
   PubMed Web of Science ®Google Scholar
• Konturek PC, Burnat G, Hahn EG. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007;58(Suppl 3):141-8
   PubMed Web of Science ®Google Scholar
• Park HJ, Hong D, Iruela-Arispe L, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002;91:143-50
   PubMed Web of Science ®Google Scholar
• Weis M, Heeschen C, Glassford AJ, Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2011;11:409
   PubMed Web of Science ®Google Scholar
• Friedman GD, Flick D, Udaltsova N, Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36
   PubMed Web of Science ®Google Scholar
• Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004;90:635-7
   PubMed Web of Science ®Google Scholar
• Nguyen DM, El-Serag HB, Henderson L, Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009;7:1299-304
   PubMed Web of Science ®Google Scholar
• Nguyen DM, Richardson P, El-Serag HB. Medications (NSAID, Statins, PPI) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010;138:2260-6
   PubMed Web of Science ®Google Scholar
• Kastelein F, Spaander MC, Biermann K, Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011;141:2000-8
   PubMed Web of Science ®Google Scholar
• Kantor ED, Onstad L, Blount PL, Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012;21:456-61
   PubMed Web of Science ®Google Scholar
• Chiang CW, Chen CY, Chiu HF, Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 2007;16:412-21
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, Epidemiologic features of CKD in Taiwan. Am J Kidney Dis 2007;49:46-55
   PubMed Web of Science ®Google Scholar
• Coogan P, Rosenberg L, Palmer JR, Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-7
   PubMed Web of Science ®Google Scholar
• Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-19
   PubMed Web of Science ®Google Scholar
• Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006;58:3-18
   PubMed Web of Science ®Google Scholar
• Meier CR, Scheinger RG, Kraenzlin ME, HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10
   PubMed Web of Science ®Google Scholar
• Rejnmark L, Plsen ML, Johnsen SP, Hip fracture risk in statin users- a population-based Danish case-control study. Osteoporos Int 2004;15:452-8
   PubMed Web of Science ®Google Scholar
• Wang PS, Solomon DH, Mogun H, HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3211-16
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Center for Drugs Statistics Methodology. ATC Index with DDDs 2003. WHO, Oslo; 2003
   Google Scholar
• Friis S, Poulsen AH, Johnsen SP, Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643-7
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Mascitelli L, Pezzetta F. The doubleedged sword of statin immunomodulation. Int J Cardiol 2009;135:128-30
   PubMed Web of Science ®Google Scholar
• Mausner-Fainberg K, Luboshits G, Mor A, The effect of HMG-CoA reductase inhibitors on naturally occurring CD+4CD+25 T cells. Atherosclerosis 2008;197:829-39
   PubMed Web of Science ®Google Scholar
• Raemer PC, Kohl K, Watzl C. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009;39:1456-65
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H, Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Villa A, Ortego M, 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apotosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002;161:17-26
   PubMed Web of Science ®Google Scholar
• Danesh FR, Sadeghi MM, Amro N, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002;99:8301-5
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19
   PubMed Web of Science ®Google Scholar
• Shibata MA, Avanaugh C, Shibata E, Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003;24:453-9
   PubMed Web of Science ®Google Scholar
• Rao S, Porter DC, Chen X, Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999;96:7797-802
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:745-51
   PubMed Web of Science ®Google Scholar